OncoMatch/Clinical Trials/NCT03686124
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
Is NCT03686124 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments for refractory cancer.
Treatment: IMA203 Product · IMA203 product- flat dose · IMA203CD8 Product · Nivolumab · IMADetect® — The study's purpose is to establish the safety and tolerability of IMA203/IMA203CD8 products with or without combination with nivolumab in patients with solid tumors that express preferentially expressed antigen in melanoma (PRAME).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: all available indicated standard of care treatment
must have received or not be eligible for all available indicated standard of care treatment
Cannot have received: stem cell transplantation
Prior stem cell transplantation
Cannot have received: solid organ transplantation
solid organ transplantation
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Stanford Cancer Institute · Stanford, California
- University of Miami Hospital and Clinics · Miami, Florida
- University of Chicago Medical Center · Chicago, Illinois
- Massachusetts General Hospital · Boston, Massachusetts
- Memorial Sloan Kettering Cancer Center · New York, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT03686124 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior stem cell transplantation, solid organ transplantation disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify